CMO taps Capsugel for early-phase supply edge

UK contract manufacturer Molecular Profiles is adding an Xcelodose 1205 powder micro-doser for capsule and vial filling. The purchase furthers the company's goal of expanding into early-phase drug trial supply production.

The Xcelodose unit, made by Pfizer's Capsugel group, provides for dosing of drug materials in quantities as small as 100 micrograms. Such precision is especially beneficial in early-phase trial materials because it eliminates the need for formulation development and stability studies, the company says.

Separately, Capsugel has garnered rights to the FlexTab dosage-form technology. The oral-delivery formulation platform, based on injection-molding technology, follows eight years of collaboration with drug giant GSK.

- see the Molecular Profiles release
- here's the FlexTab announcement


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.